MA39447A1 - (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine - Google Patents

(s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine

Info

Publication number
MA39447A1
MA39447A1 MA39447A MA39447A MA39447A1 MA 39447 A1 MA39447 A1 MA 39447A1 MA 39447 A MA39447 A MA 39447A MA 39447 A MA39447 A MA 39447A MA 39447 A1 MA39447 A1 MA 39447A1
Authority
MA
Morocco
Prior art keywords
pirlindole
pharmaceutically acceptable
acceptable salts
medicine
pain
Prior art date
Application number
MA39447A
Other languages
English (en)
Other versions
MA39447B1 (fr
Inventor
Filipe Augusto Eugénio Pardal
Pedroso Pedro Filipe Eufrásio
Pecorelli Susana Marques Almeida
Caixado Carlos Alberto Eufrásio Casimiro
Ana Sofia Da Conceição Lopes
João Carlos Damil
Original Assignee
Tecnimede Soc Tecnico-Medicinal S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Soc Tecnico-Medicinal S A filed Critical Tecnimede Soc Tecnico-Medicinal S A
Publication of MA39447A1 publication Critical patent/MA39447A1/fr
Publication of MA39447B1 publication Critical patent/MA39447B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne le composé (s)-pirlindole ou ses sels pharmaceutiquement acceptables, ainsi que des compositions pharmaceutiques comprenant ceux-ci pour une utilisation dans le traitement thérapeutique et la prévention de la douleur.
MA39447A 2014-05-09 2014-05-09 Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine MA39447B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000029 WO2015171005A1 (fr) 2014-05-09 2014-05-09 (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine

Publications (2)

Publication Number Publication Date
MA39447A1 true MA39447A1 (fr) 2017-10-31
MA39447B1 MA39447B1 (fr) 2018-05-31

Family

ID=50819931

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39447A MA39447B1 (fr) 2014-05-09 2014-05-09 Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine

Country Status (30)

Country Link
US (1) US9814712B2 (fr)
EP (1) EP3057589B1 (fr)
JP (1) JP6768520B2 (fr)
KR (1) KR102298676B1 (fr)
CN (1) CN106456637B (fr)
AU (1) AU2014393490B2 (fr)
CA (1) CA2948598C (fr)
CY (1) CY1119532T1 (fr)
DK (1) DK3057589T3 (fr)
EC (1) ECSP16086247A (fr)
ES (1) ES2649492T3 (fr)
HR (1) HRP20171651T1 (fr)
HU (1) HUE035071T2 (fr)
IL (1) IL248855B (fr)
LT (1) LT3057589T (fr)
MA (1) MA39447B1 (fr)
MX (1) MX368734B (fr)
NO (1) NO3057589T3 (fr)
NZ (1) NZ726132A (fr)
PH (1) PH12016502233A1 (fr)
PL (1) PL3057589T3 (fr)
PT (1) PT3057589T (fr)
RS (1) RS56591B1 (fr)
RU (1) RU2695647C2 (fr)
SA (1) SA516380264B1 (fr)
SI (1) SI3057589T1 (fr)
SM (1) SMT201700519T1 (fr)
TN (1) TN2016000498A1 (fr)
UA (1) UA118474C2 (fr)
WO (1) WO2015171005A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2988983T3 (es) * 2014-05-09 2024-11-22 Tecnimede Sociedade Tecnico Medicinal S Sales de mandelato de enantiómeros de pirlindol para uso en medicina
SI3054950T1 (sl) 2014-05-09 2017-12-29 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (r)-pirindol in njegove farmacevtsko sprejemljive soli za uporabo v medicini
EP3392250A1 (fr) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation de l'anneau de pipérazine pour la synthèse de pyrazinocarbazole
EP3392251A1 (fr) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation des enantiomères de pirlindole et leurs sels
MX2018011142A (es) 2018-09-13 2019-10-10 Federico Amezcua Amezcua Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.
EP3900716A1 (fr) 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Co-cristal de gabapentine, de kétoprofène et de lysine, compositions pharmaceutiques et leur utilisation médicale
CN117717546B (zh) * 2023-10-20 2026-06-12 四川大学华西医院 一种吲哚类衍生物在制备预防和/或治疗疼痛的药物中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006504795A (ja) * 2002-10-03 2006-02-09 サイプレス バイオサイエンス， インコーポレイテッド 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
KR20050101537A (ko) * 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
KR20060117909A (ko) * 2003-09-15 2006-11-17 벡투라 리미티드 폐 흡입에 의한 조루 치료용 제약학적 조성물
EP1688161A1 (fr) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis
ES2988983T3 (es) * 2014-05-09 2024-11-22 Tecnimede Sociedade Tecnico Medicinal S Sales de mandelato de enantiómeros de pirlindol para uso en medicina

Also Published As

Publication number Publication date
SA516380264B1 (ar) 2019-07-29
NZ726132A (en) 2019-02-22
KR102298676B1 (ko) 2021-09-07
LT3057589T (lt) 2017-11-27
SI3057589T1 (sl) 2017-12-29
PH12016502233A1 (en) 2017-02-06
DK3057589T3 (da) 2017-11-13
ECSP16086247A (es) 2017-02-24
PL3057589T3 (pl) 2018-01-31
CN106456637A (zh) 2017-02-22
HUE035071T2 (en) 2018-05-02
IL248855A0 (en) 2017-01-31
AU2014393490A1 (en) 2016-11-24
PT3057589T (pt) 2017-11-29
RU2016148183A3 (fr) 2018-06-13
CA2948598C (fr) 2021-06-08
ES2649492T3 (es) 2018-01-12
JP2017518979A (ja) 2017-07-13
TN2016000498A1 (en) 2018-04-04
US20170143709A1 (en) 2017-05-25
RU2016148183A (ru) 2018-06-13
EP3057589A1 (fr) 2016-08-24
RS56591B1 (sr) 2018-02-28
NO3057589T3 (fr) 2017-12-30
RU2695647C2 (ru) 2019-07-25
EP3057589B1 (fr) 2017-08-02
KR20170002434A (ko) 2017-01-06
AU2014393490B2 (en) 2020-01-02
IL248855B (en) 2020-05-31
CN106456637B (zh) 2020-06-09
MX368734B (es) 2019-10-14
US9814712B2 (en) 2017-11-14
HRP20171651T1 (hr) 2017-12-15
CA2948598A1 (fr) 2015-11-12
MA39447B1 (fr) 2018-05-31
SMT201700519T1 (it) 2018-01-11
CY1119532T1 (el) 2018-03-07
MX2016014699A (es) 2017-05-02
UA118474C2 (uk) 2019-01-25
WO2015171005A1 (fr) 2015-11-12
JP6768520B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
PH12016502353A1 (en) Pharmaceutical composition
ZA201607489B (en) Combination comprising a glucocorticoid and edo-s101
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
ZA201906153B (en) Pharmaceutical compositions for combination therapy
WO2015165964A8 (fr) Traitement et prévention de la maladie d'alzheimer
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MX2019013912A (es) Combinacion de un antagonista del receptor 5-ht6 y un inhibidor de acetilcolinesterasa para su uso en el tratamiento de la enfermedad de alzheimer en una subpoblacion de pacientes portadores de alelos apoe4.
TH167851A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
TH168999A (th) สารยับยั้งของ rorc2 ประเภทเฮเทอโรไบไซโคลแอริล และวิธีการใช้ของมัน
NZ724285A (en) Agent for improving or preventing progression of chronic kidney disease
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
FR3023166B1 (fr) Utilisation d'une composition pharmaceutique renfermant une pectine a titre de principe actif, dans la prevention et/ou le traitement des lesions cutanees impliquant un caractere inflammatoire
MA39188A1 (fr) Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci